Propanc Biopharma Management
Management criteria checks 4/4
Propanc Biopharma's CEO ist James Nathanielsz , ernannt in Oct 2007, hat eine Amtszeit von 16.17 Jahren. Die jährliche Gesamtvergütung beträgt $430.28K , bestehend aus 92.9% Gehalt und 7.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.039% der Aktien des Unternehmens, im Wert von $77.19 . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 13 Jahre bzw. 7.9 Jahre.
Key information
James Nathanielsz
Chief executive officer
US$430.3k
Total compensation
| CEO salary percentage | 92.9% |
| CEO tenure | 16.5yrs |
| CEO ownership | 0.01% |
| Management average tenure | 13.3yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$3m |
| Sep 30 2023 | n/a | n/a | -US$3m |
| Jun 30 2023 | US$430k | US$400k | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$3m |
| Dec 31 2022 | n/a | n/a | -US$3m |
| Sep 30 2022 | n/a | n/a | -US$4m |
| Jun 30 2022 | US$452k | US$320k | -US$3m |
| Mar 31 2022 | n/a | n/a | -US$3m |
| Dec 31 2021 | n/a | n/a | -US$3m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | US$541k | US$299k | -US$2m |
| Mar 31 2021 | n/a | n/a | -US$43k |
| Dec 31 2020 | n/a | n/a | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | US$590k | US$358k | -US$5m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | n/a | n/a | -US$6m |
| Sep 30 2019 | n/a | n/a | -US$5m |
| Jun 30 2019 | US$989k | US$422k | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$6m |
| Dec 31 2018 | n/a | n/a | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | US$576k | US$285k | -US$7m |
| Mar 31 2018 | n/a | n/a | -US$7m |
| Dec 31 2017 | n/a | n/a | -US$7m |
| Sep 30 2017 | n/a | n/a | -US$9m |
| Jun 30 2017 | US$307k | US$244k | -US$8m |
Vergütung im Vergleich zum Markt: JamesDie Gesamtvergütung ($USD430.28K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD740.57K).
Entschädigung vs. Einkommen: JamesDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
CEO
James Nathanielsz (49 yo)
16.5yrs
Tenure
US$430,284
Compensation
Mr. James Nathanielsz serves as the Executive Chairman, Secretary and Treasurer of Propanc Biopharma, Inc., and has been its Director since October 15, 2007. He has been Chief Executive Officer at Propanc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 16.5yrs | US$430.28k | 0.012% $ 14.0 | |
| Chief Scientific Officer | 4.9yrs | US$35.99k | 0.0047% $ 5.5 | |
| Chief Medical Officer & Member of Scientific Advisory Board | 13.3yrs | US$18.23k | no data |
13.3yrs
Average Tenure
Erfahrenes Management: Das Managementteam von PPCB ist erfahren und erfahren (durchschnittliche Amtszeit: 13 Jahre).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 16.5yrs | US$430.28k | 0.012% $ 14.0 | |
| Chief Scientific Officer | 16.2yrs | US$35.99k | 0.0047% $ 5.5 | |
| Chief Medical Officer & Member of Scientific Advisory Board | no data | US$18.23k | no data | |
| Member of Scientific Advisory Board | 4.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Independent Non-Executive Director | 3.3yrs | US$84.00k | 0.0039% $ 4.5 |
8.3yrs
Average Tenure
66yo
Average Age
Erfahrener Vorstand: PPCBDie Vorstandsmitglieder gelten als erfahren (7.9 Jahre durchschnittliche Amtszeit).